Medicus Pharma Ltd Ordinary Shares MDCX 深 滬
已收盤 12-05 16:00:00 美东时间
2.05
+0.130
+6.77%
華盛通- 最 高2.10
- 今 開2.01
- 成交量 37.09万股
- 最 低 1.93
- 昨 收 1.92
- 總市值 3652.34万
- 52周最高 8.94
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 1.675
- 委 比 88.61%
- 總股本 1781.63万
- 歷史最高 8.94
- 量 比 0.77
- 振 幅 8.85%
- 歷史最低 1.675
- 每 手 1
- 風險率 1.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Medicus Pharma Elevates President Carolyn Bonner to CFO as Co-Founder Jim Quinlan Steps Down for Health Reasons
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
12-01 20:37
Medicus Pharma Seeks Fast-Track FDA Voucher for New Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
11-17 20:35
Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.29) by 286.21 percent. This is a 366.67 percent decrease over losses of $(0.24) per share
11-15 06:01
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:MDCX) with a Buy and maintains $27 price target.
11-13 21:10
Medicus Pharma Partners With Gorlin Syndrome Alliance To Enhance Access To SKINJECT For Gorlin Syndrome Patients
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-29 19:34
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Medicus Pharma collaborates with Gorlin Syndrome Alliance to advance access to SKINJECT™, a novel therapy for Gorlin syndrome patients with basal cell carcinomas. SKINJECT™ uses microneedle arrays to deliver doxorubicin, targeting localized treatments for skin cancers. The collaboration aims to establish an Expanded Access IND Program, collecting real-world data to support future regulatory filings. Gorlin syndrome affects 1 in 31,000 people, cau...
10-29 11:30
Medicus Pharma Begins UAE Trial for Non-Invasive Skin Cancer Treatment
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased
10-22 19:35
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
